Select company
- Ticker/CompanyMarket Cap.
No results found
Select metric
Pick a metric...
$ -24.27MEarnings Before Interest Taxes & Depreciation Amortization (EBITDA)
VS
Market
Sector
Industry
History
$ 14.15Close
$ 6.7 - $ 682.84 52-Week Range
Ticker Information
Ticker
RNAZCompany Name
TRANSCODE THERAPEUTICS INCSector
HealthcareIndustry
BiotechnologyExchange
NASDAQTRANSCODE THERAPEUTICS INC - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) Chart Analysis (TTM)
From
Zoom
1Y
3Y
5Y
10Y
RNAZ - EBITDA Historical data
| Date | Depreciation, Amortization & Accretion | Earning Before Interest & Taxes (EBIT) | Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) |
|---|---|---|---|
| 6/30/2025 | $ 314.99K | $ -24.59M | $ -24.27M |
| 3/31/2025 | $ 444.38K | $ -25.5M | $ -25.05M |
| 12/31/2024 | $ 534.86K | $ -16.73M | $ -16.19M |
| 9/30/2024 | $ 552.17K | $ -14.85M | $ -14.29M |
| 6/30/2024 | $ 563.44K | $ -17.84M | $ -17.27M |
| 3/31/2024 | $ 558.19K | $ -16.99M | $ -16.43M |
| 12/31/2023 | $ 516.75K | $ -18.49M | $ -17.97M |
| 9/30/2023 | $ 406.08K | $ -19.59M | $ -19.19M |
| 6/30/2023 | $ 292.1K | $ -18.58M | $ -18.29M |
| 3/31/2023 | $ 177.2K | $ -18.91M | $ -18.73M |
Key Performance Insights, Last 5 Years
- TRANSCODE THERAPEUTICS INC's latest trailing twelve months (TTM) EBITDA stands at $ -1.95M.
- Over the past 5 years, TRANSCODE THERAPEUTICS INC's average EBITDA has been $ -15.49M.
- The median EBITDA for TRANSCODE THERAPEUTICS INC during this period was $ -16.85M
- TRANSCODE THERAPEUTICS INC reached its highest EBITDA over the past 5 years at $ -1.95M.
- The lowest EBITDA recorded by TRANSCODE THERAPEUTICS INC in the same timeframe $ -25.05M
Similar metrics to EBITDA:
- Depreciation, Amortization & Accretion - [Cash Flow Statement] A component of operating cash flow [NCFO] representing the aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a non-cash item, the net amount is added back to net income when calculating cash provided by operations.
- Enterprise Value over EBITDA - [Calculation] Measures a company’s Enterprise Value [EV] in relation to its earnings before interest, taxes, depreciation, and amortization [EBITDA].
- EBITDA per Share - [Calculation] The amount of earnings before interest, taxes, depreciation, and amortization attributed to each share, calculated as [EBITDA] divided by the weighted average number of shares [SharesWA] after adjusting for [ShareFactor].
- Earning Before Interest & Taxes (EBIT) - [Income Statement] Earnings before interest and taxes measures a company's net income [NetInc] prior to the deduction of interest [IntExp] and tax expenses [TaxExp].
- EBITDA Margin - [Calculation] A company’s [EBITDA] as a percentage of [Revenue]. Measures how much earnings a company produces for each dollar of revenue generated before interest, taxes, depreciation and amortization.
Definition of Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)
[Calculation] EBITDA is a non-GAAP accounting metric that lets investors asses profitability net of expenses dependent on financing decision, tax strategy and depreciation schedules. It is calculated by adding depreciation and amortisation expenses [DepAmor] back to [EBIT].EBIT + DepAmor
(=) EBITDA EBITDA for TRANSCODE THERAPEUTICS INC is calculated as follows: EBIT [ $ -1.95M ] + DepAmor [ $ 0 ]
(=) EBITDA [ $ -1.95M ] RNAZ - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA), Last 5 years
$ -25.05M
Minimum
Mar 31, 2025
$ -1.95M
Maximum
Dec 31, 2020
$ -15.49M
Average
$ -16.85M
Median
EBITDA Benchmark AnalysisMarket
The chart above depicts the distribution of EBITDA for companies in the Total Stock Market. The average EBITDA of the companies is $ 58.9M with a standard deviation of $ 167.01M.
The following table provides additional summary stats:
EBITDA in the Market:
| filtered constituents | 3.24K |
|---|---|
| min | $ -493.3M |
| max | $ 590.6M |
| average | $ 58.9M |
| median | $ 8.92M |
| std | $ 167.01M |